In a clinical trial in patients with type 2 diabetes and heart failure, the SGLT2 inhibitor empagliflozin, in addition to the loop diuretic furosemide, caused a significant increase in urine volume compared with furosemide alone [54]. Here, SLC5A2 is linked to type 2 diabetes mellitus.